Pharmala Biotech Holdings Inc. (MDMA.CN) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-266.4%

-CA$0.31

vs CA$0.19 price

Levered DCF

-CA$0.33

After debt service

Piotroski score

2 / 9

Weak

Altman Z-score

5.56

Safe zone

Rating

D+

Overall 1 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021
P/E	-6.19×	-9.14×	-23.91×	-4.2×	-2.65×
P/B	5.47×	3.8×	13.44×	2.18×	2.5×
P/S	22.2×	7.27×	34.95×	53.16×	0×
EV / EBITDA	-6.47×	-12.4×	-26.27×	-3.39×	-1.66×
Gross margin	-139.6%	85.7%	85.4%	97.1%	0.0%
Operating margin	-355.6%	-62.2%	-143.4%	-1262.4%	0.0%
Net margin	-359.2%	-79.6%	-146.6%	-1262.4%	0.0%
Current ratio	1.71×	1.14×	0.69×	2.56×	18.28×
Debt / equity	0×	0×	0.18×	0×	0×
Interest coverage	0×	0×	0×	0×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Return on equity	-88.5%	-41.6%	-56.4%	-51.7%	-94.5%
Return on invested capital	-87.6%	-26.3%	-46.6%	-51.7%	-94.5%
Return on assets	-63.6%	-28.4%	-32.3%	-42.3%	-89.8%
Free cash flow yield	-7.8%	-7.3%	-4.6%	-39.0%	-6.6%
Earnings yield	-16.2%	-10.9%	-4.2%	-23.7%	-37.8%
Enterprise value	CA$13.4M	CA$7.1M	CA$18.7M	CA$3.3M	CA$4.2M
Net debt / EBITDA	0.02×	0.73×	-0.08×	0.88×	0.99×
Cash conversion cycle (days)	135	63	-1,544	-40,494	-166,815